The European Commission, or European Medicines Agency, has approved Roche’s drug Kadcyla as adjuvant therapy for HER2-positive early breast cancer. The U.S. Food and Drug Administration (FDA) approved Kadcyla in May and has already been prescribed for patients with early breast cancer.

The post EU Approves Roche’s Breast Cancer Drug Kadcyla appeared first on Latest Health & Medical News – Myhealthyclick.com.